bluuebunny/crossref_metadata_2025_split huggingface dataset:
O16 Positron emission tomography - computed tomography: an important diagnostic tool in the giant cell arteritis fast track pathway
Authors: Ludwig Dalia R , Morris Vanessa , Shashidhara Anush , Voo Stefan , Reshat Reshat 
Published: April 2021

Abstract
Background/Aims
Giant cell arteritis (GCA) is a systemic vasculitis affecting the temporal arteries and large vessels, including the aorta, in 25% of cases. Incidence of vertebral artery involvement is unknown likely owing to the reliance on conventional diagnostics including temporal artery biopsy (TAB) and temporal/axillary ultrasound which evade the vertebral arteries. These tests lose sensitivity soon after steroid initiation. Early specialist assessment and diagnostics, as part of a fast track pathway (FTP), can overcome this challenge. We present the first 12 months data from our FTP. To our knowledge this is the first GCA-FTP in the UK to utilise positron emission tomography - computed tomography (PET-CT) as an early diagnostic tool so we present a unique cohort of patients.
Methods
Cohort 1: 40 patients, diagnosed between 2015-2019, before FTP implementation. Time from steroid initiation to temporal artery ultrasound (TAUS) and TAB was recorded. Cohort 2: 35 patients referred after pathway implementation. 21 had a positive diagnosis. Time from steroid initiation to diagnostic test was recorded.
Results
Cohort 1: 26 (65%) patients had TAB; 3 (7.5%) had TAUS. The average time from starting steroid to investigation was 6 and 2 days respectively. Cohort 2: 17 (48%) had TAB, 30 (86%) had TAUS, 28 (80%) had PET-CT. In confirmed diagnoses, time from steroid initiation to investigations was 6.6 days, 1 day and 2.5 days respectively. In negative diagnoses time frames were 11.5, 1.5 and 2.3 days respectively. Table 1 shows sensitivity and specificity of these tests. Table 1. Sensitivity and specificity comparison between diagnostic tests
Conclusion
Combining TAUS and PET-CT allows for high diagnostic accuracy without the need for invasive biopsy. 24% of patients had negative or inconclusive ultrasound and/ or negative biopsy but confirmed vasculitis on PET-CT. 50% of this cohort had vertebral involvement only. PET-CT has an important role in detecting extracranial particularly vertebral arteritis, where biopsy and ultrasound are unreliable. Our pathway design with the inclusion of PET-CT, enables us to capture all patients with GCA and satisfy NHS England criteria for tocilizumab use in refractory GCA. Continued evaluation of PET-CT and its role in predicting vascular complications is required.
Disclosure
D.R. Ludwig: None. V. Morris: None. A. Shashidhara: None. S. Voo: None. R. Reshat: None.
O32 Serious infection with tocilizumab compared to TNF-inhibitors and other bDMARDS in rheumatoid arthritis patients: does line of therapy matter?
Authors: Lauper Kim , Kearsley-Fleet Lianne , Davies Rebecca , Watson Kath , Lunt Mark , Hyrich Kimme L 
Published: April 2021

Abstract
Background/Aims
In the real-world, tocilizumab is prescribed to a population of patients different from those prescribed TNF-inhibitors, often older with longer disease duration, worse functional status and more previous b- or tsDMARDs. The aim of this study was to evaluate if and how the risk of serious infection on tocilizumab and other bDMARDs differs when stratifying by line of therapy in a real-world population of rheumatoid arthritis patients.
Methods
We included patients registered in the BSRBR-RA treated with tocilizumab, etanercept, adalimumab, infliximab, certolizumab, abatacept or rituximab, including biosimilars. Primary outcome was the occurrence of a serious infection (defined as infection requiring hospitalisation, intravenous antibiotics or resulting in death). Primary covariate of interest was line of therapy (from first to fifth line of therapy). Every change to another b- or tsDMARD was considered a new line of therapy, but not a change between a bio-original and a biosimilar.
Hazard ratios (HR) of serious infections were estimated using an inverse probability weighted Cox regression, based on a propensity score including baseline patient and disease characteristics, and adjusting for time in study (see table). The reference group was etanercept, which included the highest number of patients. Treatment exposure was analysed without and with stratification by line of therapy.
Results
A total of 33,916 treatment courses were included (Table) contributing to 62,532 years of follow-up. Compared to etanercept, participants starting abatacept, tocilizumab and rituximab were older, had more previous bDMARDs, longer disease duration and more comorbidities. The crude HR of serious infections were higher with infliximab and adalimumab, lower with certolizumab and rituximab, and not significantly different for abatacept and tocilizumab compared to etanercept. After adjustment, HR of serious infections were higher with tocilizumab, adalimumab and infliximab. However, when stratified by line of therapy, HR were no longer significantly different compared to etanercept for tocilizumab, adalimumab and infliximab for most lines of therapy.
Conclusion
Whilst initially there appears to be a difference in rates of serious infections between biologic therapies, line of therapy may be a confounding factor when comparing the risk of serious infections between bDMARDs.
Disclosure
K. Lauper: Honoraria; Gilead-Galapagos. Grants/research support; AbbVie. Other; AbbVie, Pfizer. L. Kearsley-Fleet: None. R. Davies: None. K. Watson: None. M. Lunt: None. K.L. Hyrich: Honoraria; AbbVie. Grants/research support; Pfizer, BMS.
P004 Rheumatologist vs pathology department: correlation of crystal identification in synovial fluid analysis
Authors: Abdalla A 
Published: April 2021

Abstract
Background/Aims
Crystal arthritis is the commonest inflammatory arthritis in adults. Diagnosis relies mostly on the correct identification of crystals under red-compensated polarized microscopy with assessment of birefringence. This is done routinely in our department when opportunity arises. Failure to appropriately identify crystals may result in lengthy hospitalisations, complications, avoidable repeated urgent visits, and unnecessary cost. We aimed to examine the agreement between rheumatology vs pathology-based microscopy for crystal analysis. There is currently no standardized pathway for synovial fluid crystal analysis in our tertiary centre in Dublin.
Methods
A prospective study at Mater Misericordiae University Hospital - Dublin, was started in Dec 2019. Synovial fluid samples were obtained from acutely inflamed joints where clinically indicated. Fresh samples which were found to contain crystals (MSU or CPP) by a rheumatology consultant or trained registrar using compensated polarized microscopy, were also simultaneously sent to our pathology laboratory to receive similar analysis. Ethical approval was granted and all patients consented for their joint fluid to receive double analysis.
Results
33 samples have been analysed to date. 13 samples of MSU crystals and 20 CPP crystals (table 1). Both rheumatologist and pathologist agreed on all but only one MSU sample. The pathologist identified CPP crystals only on 2/20 samples. The fluid analysis was carried out within the same working day by rheumatologist Vs. median of 2.3 working days for the result by the pathologist.
Conclusion
The study showed a high agreement between rheumatologists and pathologists on identification of MSU crystals (92%), but very poor agreement on CPP crystals (only 10%). A quality improvement project is currently underway to address this issue and bridge the gap. Majority of Rheumatologists don't routinely perform crystal analysis using polarized microscopy and rely on their local cellular pathology lab for the results. Rheumatologists need to liaise with their local pathologists to optimise and streamline the process of crystal microscopy specially CPP crystals. P004 Table 1:crystals samples analysed through rheumatology and pathologyCPPD positiveMSU positiveRheumatologist2013Pathologist212Total2013
Disclosure
A. Abdalla: None.
P044 Tibia honest, it takes a lot of spine to diagnose DISC
Authors: Ng Wan Lin , Anjum Aqeel , Devlin Joe , Fraser Alexander 
Published: April 2021

Abstract
Background/Aims
CRMO is a rare autoinflammatory condition characterised by sterile bone osteolytic lesions which is described mainly in children with a female preponderance.
Methods
A 31 year-old male presented with a 4-week history of productive cough, abdominal pain, left sided chest pain and right hip pain. He is a smoker with a background of heroin addiction and alcohol abuse. He was homeless and no family history available as he was fostered. His chest radiography was unremarkable but he had inflammatory markers. He was treated for as chest infection and heroin withdrawal. CT abdomen and pelvis demonstrated multiple osteolytic lesions in the pelvis, sternum, thoracic and lumbar spine. His HIV, Quantiferon and blood cultures were negative. His immunoglobulins, urine Bence Jones protein and echocardiogram were normal. In-depth assessment by the Infectious Disease team failed to isolate an infective pathogen. Bone marrow aspirate and trephine were unremarkable. Two CT-guided bone biopsies done twice showed plasma cells and macrophages. His condition deteriorated rapidly over 2 months. He mobility was reduced to wheelchair-bound and had dramatic 10kg weight loss.
Results
In the absence of an infective or malignant cause, the Rheumatology service was consulted. Having reviewed the extensive data available, he was diagnosed with a likely but unusually aggressive form of adult-onset chronic recurrent multifocal osteomyelitis (CRMO). He was commenced initially on IV methylprednisolone, zoledronic acid, methotrexate and, etoricoxib. Subsequently he was treated with, tocilizumab and teriparatide. Whole body MRI revealed numerous other lesions not evident on previous imaging including lesions of the distal right humerus, proximal right femur and both tibias. His symptoms and inflammatory markers improved substantially over several days following treatment. A repeat full body MRI demonstrated dramatic improvement in the bony lesions. Soon he was able to walk again and gained some weight before he absconded from the hospital. His treatment was changed to tocilizumab infusion and denosumab injection to facilitate compliance.
Conclusion
This is an unusual fascinating case which posed a significant diagnostic dilemma. Ruling out infection particularly in great challenge in diagnosing CRMO in a male adult who is homeless and a heroin abuser presenting with multifocal osteolytic lesions was challenging. The severity of his condition necessitated using novel treatments such as tocilizumab.
Disclosure
W. Ng: None. A. Anjum: None. J. Devlin: None. A. Fraser: None.
P081 Arthritis, artists and art opporunities for education
Authors: Amar Soha , Lloyd Mark 
Published: April 2021

Abstract
Background/Aims
The role of art in rheumatology is under-investigated. Several well-known artists have suffered from rheumatic disease. Their insights and achievements potentially provide reassurance and encouragement to our patients. Creating art may also offer therapeutic benefits for patients. Finally, the artistic environment can affect mood and behaviour. We highlight several inspirational artists.
Methods
Four artists offer valuable insights: Michaelangelo (d. 1564) was able to master sculpture, painting and architecture despite hand osteoarthritis and persisted in working until his death, age 89.
Pierre-Auguste Renoir (d. 1919) developed severe RA aged 50. He continued to paint for the rest of his life, being carried to outdoor scenes on a sedan and designing an innovative rolling canvas to complete some of his finest work. He painted on small pieces of wood at night to distract from his arthritic pain.
Frida Kahlo (d.1954), the Mexican artist, experienced chronic generalised pain and fatigue in keeping with fibromyalgia. This was after a bus accident at eighteen resulted in multiple pelvic and vertebral fractures. Self-portraiture became the cornerstone of her bold art during the solitude of her convalescence.
Maud Lewis (d.1970), the Canadian folk painter, had JIA in early childhood resulting in a limp and severe hand changes. She spent much time indoors due to her pain and the ridicule faced from her peers. She developed an eagerness for drawing; to the extent that she painted on any surface she could find of her small cottage.
Results
These artists’ own words reveal the resilience they gained from their art. Renoir stated: 'Out of doom and misery the most beautiful song may rise'. Lewis reported ‘As long as I’ve got a brush in front of me, I’m alright.’, whilst Kahlo was similarly quoted to say ‘I am broken. But I am happy to be alive as long as I can paint’. A small study in 2017 with 17 patients with RA showed improvement not only in hand function but also self-perception and quality of life after participating in daily art-based intervention (origami, painting and clay modelling) for four weeks.
Furthermore, a common theme between these famous artists was how they favoured bright colours in their artwork, which may have positive effects on mood. Colouring can reduce stress in children in paediatric waiting rooms. Within other settings, research suggests that visual art depicting nature can reduce anxiety in emergency department waiting rooms.
Conclusion
Although exceptionally talented people, the artists discussed show the inspiring possibilities of creativity despite severe rheumatic disease. We suggest sharing these stories with our patients and considering further study into the therapeutic potential of creating art in rheumatic conditions. Attention should be paid to the artistic environment in which we see our patients.
Disclosure
S. Amar: None. M. Lloyd: None.
P121 The efficacy of treatment interventions on fatigue in adolescents with juvenile idiopathic arthritis: a literature review
Authors: Moshtael Sebastian , Khanom Sonia , McDonagh Janet E 
Published: April 2021

Abstract
Background/Aims
Fatigue has been reported by young people and professionals alike as a major challenge for people living with juvenile idiopathic arthritis (JIA) . It remains unclear as to how therapeutic interventions impacts on this major symptom. The aim of this review was to determine the current evidence for the effectiveness of therapeutic interventions, non- pharmacological and pharmacological, on improving fatigue in adolescents with JIA.
Methods
Three electronic databases (MEDLINE, EMBASE, PsycINFO) were searched from 2000 to Feb 2020; in addition to manual searches. Articles were eligible for inclusion if they (i) were original research papers, (ii) had fatigue as a primary outcome measure (iii) included adolescents (10-25 years) and (iv) were available in the English language.
Results
Of the 3,142 records identified, 31 underwent full text assessment and 4 studies were included in the qualitative synthesis including 2 from the Netherlands, 1 Germany, and 1 from Canada. The total number of participants across the 4 studies was 824. Three were randomised controlled trials of nonpharmacological interventions and one was a cohort study from a national drug registry including older adolescents JIA (mean: 19-years). Measurement tools included the Paediatric Quality of life multidimensional fatigue scale, (2 studies), the Checklist for Individual Strength CIS-20 (1 study), a numeric rating scale (1 study). In one study a visual analogue scale for energy level was also utilised. In 2 studies baseline prevalence of fatigue was reported as 60% and 76% respectively. Significant reduction in fatigue was observed in all three nonpharmacological studies. In the registry study, fatigue was noted to be prevalent in spite of the disease being in inactive or minimally active on biologic therapy. In 3 studies the relationship between health-related quality of life and fatigue was highlighted and showed a decreased quality of life in fatigued young people.
Conclusion
Fatigue is a significant problem in JIA during adolescence and influences quality of life. Improvements in fatigue with non-pharmacological interventions have been reported. However, at present, data is insufficient to conclusively decide which treatment intervention is most efficacious in treating fatigue in young people with JIA. Fatigue should be considered as an important outcome measure for the management of JIA in future evaluations of interventions.
Disclosure
S. Moshtael: None. S. Khanom: None. J.E. McDonagh: None.
P129 Predictors of low bone mineral density in rheumatoid arthritis
Authors: Swar Malika A , Bukhari Marwan 
Published: April 2021

Abstract
Background/Aims
Osteoporosis (OP) is an extra-articular manifestation of rheumatoid arthritis (RA) that leads to increased fracture susceptibility due to a variety of reasons including immobility and cytokine driven bone loss. Bone loss in other populations has well documented risk factors. It is unknown whether bone loss in RA predominantly affects the femoral neck or the spine. This study aimed to identify independent predictors of low bone mineral density (BMD) in patients RA at the lumbar spine and the femoral neck.
Methods
This was a retrospective observational cohort study using patients with Rheumatoid arthritis attending for a regional dual X-ray absorptiometry (DEXA) scan at the Royal Lancaster Infirmary between 2004 and 2014. BMD in L1-L4 in the spine and in the femoral neck were recorded. The risk factors investigated were steroid use, family history of osteoporosis, smoking, alcohol abuse, BMI, gender, previous fragility fracture, number of FRAX(tm) risk factors and age. Univariate and Multivariate regression analysis models were fitted to explore bone loss at these sites using BMD in g/cm2 as a dependant variable. .
Results
1,527 patients were included in the analysis, 1,207 (79%) were female. Mean age was 64.34 years (SD11.6). mean BMI was 27.32kg/cm2 (SD 5.570) 858 (56.2%) had some steroid exposure . 169(11.1%) had family history of osteoporosis. fragility fracture history found in 406 (26.6%). 621 (40.7%) were current or ex smokers . There was a median of 3 OP risk factors (IQR 1,3) The performance of the models is shown in table one below. Different risk factors appeared to influence the BMD at different sites and the cumulative risk factors influenced BMD in the spine. None of the traditional risk factors predicted poor bone loss well in this cohort. P129 Table 1:result of the regression modelsCharacteristicB femoral neck95% CIpB spine95%CIpAge at scan-0.004-0.005,-0.003&lt;0.01-0.0005-0.002,0.00050.292Sex-0.094-0.113,-0.075&lt;0.01-0.101-0.129,-0.072&lt;0.01BMI (mg/m2)0.0080.008,0.0101&lt;0.010.01130.019,0.013&lt;0.01Fragility fracture-0.024-0.055,0.0060.12-0.0138-0.060,0.0320.559Smoking0.007-0.022,0.0350.650.0286-0.015,0.0720.20Alcohol0.011-0.033,0.0 5560.620.0544-0.013,0.1120.11Family history of OP0.012-0.021,0.0450.470.0158-0.034,0.0650.53Number of risk factors-0.015-0.039,0.0080.21-0.039-0.075,-0.0030.03steroids0.004-0.023,0.0320.030.027-0.015,0.0690.21
Conclusion
This study has shown that predictors of low BMD in the spine and hip are different and less influential than expected in this cohort with RA . As the FRAX(tm) tool only uses the femoral neck, this might underestimate the fracture risk in this population. Further work looking at individual areas is ongoing.
Disclosure
M.A. Swar: None. M. Bukhari: None.
Increasing Nursing Student Success With Early Individual Remediation
Authors: Fairchild Faye A. 
Published: April 2021

Abstract
With the implementation of five remediation strategies immediately after the first failed exam in a pharmacology course, this quality improvement study demonstrated an increase in retention of at-risk associate degree nursing students. Unit exam scores and course failure rates were measured before and after implementation. Twelve of 14 students who completed the remediation demonstrated a statistically significant increase in scores from the first failed exam to the last exam taken. The mean increase was 17.3 percentage points (p < .0001, 95 percent confidence interval [13.3, 20.9]). Cohen’s d, which equaled 0.604, indicated a significant increase in course pass rates.
Assisted Fluid Management Software Guidance for Intraoperative Fluid Administration
Authors: Maheshwari Kamal , Malhotra Gaurav , Bao Xiaodong , Lahsaei Peiman , Hand William R. , Fleming Neal W. , Ramsingh Davinder , Treggiari Miriam M. , Sessler Daniel I. , Miller Timothy E. ,   on behalf of the Assisted Fluid Management Study Team
Published: April 2021

Background
Excessive or inadequate fluid administration causes complications, but despite this, fluid administration during noncardiac surgery is highly variable. Goal-directed management helps optimize the amount and timing of fluid administration; however, implementation is difficult because algorithms are complex. The authors therefore tested the performance of the Acumen Assisted Fluid Management software (Edwards Lifesciences, USA), which is designed to guide optimal intravenous fluid administration during surgery.

Methods
In this multicenter, prospective, single-arm cohort evaluation, the authors enrolled 330 adults scheduled for moderate- to high-risk noncardiac surgery that required arterial catheter insertion and mechanical ventilation. Clinicians chose a fluid strategy based on a desired 10%, 15%, or 20% increase in stroke volume (SV) in response to a fluid bolus. Dedicated fluid management software prompted “test” or “recommended” boluses, and clinicians were free to initiate a “user” bolus of 100 to 500 ml of crystalloid or colloid. Clinicians were free to accept or decline the software prompts. The authors primarily compared the fraction of software-recommended boluses that produced suitable increases in SV to a 30% reference rate. On an exploratory basis, we compared responses to software-recommended and clinician-initiated boluses.

Results
Four hundred twenty-four of 479 (89%) software-recommended fluid boluses and 508 of 592 (86%) clinician-initiated fluid boluses were analyzed per protocol. Of those, 66% (95% CI, 62 to 70%) of delivered fluid boluses recommended by the software resulted in desired increases in SV, compared with the 30% reference rate, whereas only 41% (95% CI, 38 to 44%) of clinician-initiated boluses did (P < 0.0001). The mean ± SD increase in SV after boluses recommended by the software was 14.2 ± 13.9% versus 8.3 ± 12.1% (P < 0.0001) for those initiated by clinicians.

Conclusions
Fluid boluses recommended by the software resulted in desired SV increases more often, and with greater absolute SV increase, than clinician-initiated boluses. Automated assessment of fluid responsiveness may help clinicians optimize intraoperative fluid management during noncardiac surgery.

Editor’s Perspective

What We Already Know about This Topic

What This Article Tells Us That Is New